SG193612A1 - Benzoic acid salt of otamixaban - Google Patents

Benzoic acid salt of otamixaban Download PDF

Info

Publication number
SG193612A1
SG193612A1 SG2013071766A SG2013071766A SG193612A1 SG 193612 A1 SG193612 A1 SG 193612A1 SG 2013071766 A SG2013071766 A SG 2013071766A SG 2013071766 A SG2013071766 A SG 2013071766A SG 193612 A1 SG193612 A1 SG 193612A1
Authority
SG
Singapore
Prior art keywords
benzoic acid
methyl
acid salt
amino
oxidopyridin
Prior art date
Application number
SG2013071766A
Other languages
English (en)
Inventor
Norbert Nagel
Bruno Baumgartner
Harald Berchtold
Timothy Ayers
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG193612A1 publication Critical patent/SG193612A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG2013071766A 2011-03-29 2012-03-27 Benzoic acid salt of otamixaban SG193612A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11305348 2011-03-29
US201161500342P 2011-06-23 2011-06-23
PCT/EP2012/055364 WO2012130821A1 (en) 2011-03-29 2012-03-27 Benzoic acid salt of otamixaban

Publications (1)

Publication Number Publication Date
SG193612A1 true SG193612A1 (en) 2013-11-29

Family

ID=44065390

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2013071766A SG193612A1 (en) 2011-03-29 2012-03-27 Benzoic acid salt of otamixaban

Country Status (21)

Country Link
US (1) US8993602B2 (cg-RX-API-DMAC10.html)
EP (1) EP2691371B1 (cg-RX-API-DMAC10.html)
JP (1) JP5959617B2 (cg-RX-API-DMAC10.html)
KR (1) KR101852226B1 (cg-RX-API-DMAC10.html)
CN (1) CN103562183B (cg-RX-API-DMAC10.html)
AU (1) AU2012234325B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013025105A2 (cg-RX-API-DMAC10.html)
CA (1) CA2830965C (cg-RX-API-DMAC10.html)
CY (1) CY1116659T1 (cg-RX-API-DMAC10.html)
DK (1) DK2691371T3 (cg-RX-API-DMAC10.html)
ES (1) ES2539236T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20150613T1 (cg-RX-API-DMAC10.html)
IL (1) IL228574A (cg-RX-API-DMAC10.html)
MX (1) MX2013011266A (cg-RX-API-DMAC10.html)
MY (1) MY161396A (cg-RX-API-DMAC10.html)
PL (1) PL2691371T3 (cg-RX-API-DMAC10.html)
PT (1) PT2691371E (cg-RX-API-DMAC10.html)
RU (1) RU2597423C2 (cg-RX-API-DMAC10.html)
SG (1) SG193612A1 (cg-RX-API-DMAC10.html)
SI (1) SI2691371T1 (cg-RX-API-DMAC10.html)
WO (1) WO2012130821A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG193932A1 (en) 2011-03-29 2013-11-29 Sanofi Sa Otamixaban formulations with improved stability
CN106565698B (zh) * 2016-08-15 2019-03-08 南京帕隆材料科技有限公司 取代噻唑类衍生物及其制备方法和用途
CN106518859B (zh) * 2016-08-15 2019-01-18 南京帕隆材料科技有限公司 噻唑类衍生物及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424334A (en) 1991-12-19 1995-06-13 G. D. Searle & Co. Peptide mimetic compounds useful as platelet aggregation inhibitors
US6080767A (en) * 1996-01-02 2000-06-27 Aventis Pharmaceuticals Products Inc. Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
IL125163A0 (en) * 1996-01-02 1999-01-26 Rhone Poulenc Rorer Pharma Substituted n-[(aminoiminomethyl or aminomethyl) phenyl] propyl amides
GB0108903D0 (en) * 2000-10-05 2001-05-30 Aventis Pharm Prod Inc Novel crystalline forms of a factor Xa inhibitor
KR101509829B1 (ko) * 2007-05-02 2015-04-06 포톨라 파마슈티컬스, 인코포레이티드 혈소판 adp 수용체 억제제로 작용하는 화합물을 이용한 병용요법
BR112012001900A2 (pt) * 2009-07-29 2016-03-15 Sanofi Sa otamixabano para tratamento de pacientes idosos com insuficiência renal e infarto do miocárdio sem elevação do st

Also Published As

Publication number Publication date
PT2691371E (pt) 2015-07-20
US20140024684A1 (en) 2014-01-23
KR101852226B1 (ko) 2018-04-25
ES2539236T3 (es) 2015-06-29
MX2013011266A (es) 2014-03-27
MY161396A (en) 2017-04-14
EP2691371B1 (en) 2015-03-18
CN103562183A (zh) 2014-02-05
RU2013148005A (ru) 2015-05-10
HRP20150613T1 (hr) 2015-07-17
IL228574A (en) 2015-07-30
BR112013025105A2 (pt) 2017-06-06
JP5959617B2 (ja) 2016-08-02
KR20140022851A (ko) 2014-02-25
CA2830965A1 (en) 2012-10-04
DK2691371T3 (da) 2015-06-22
SI2691371T1 (sl) 2015-07-31
HK1189584A1 (en) 2014-06-13
AU2012234325A1 (en) 2013-10-17
AU2012234325B2 (en) 2016-08-11
CN103562183B (zh) 2015-12-23
WO2012130821A1 (en) 2012-10-04
CA2830965C (en) 2019-04-09
CY1116659T1 (el) 2017-03-15
PL2691371T3 (pl) 2015-08-31
IL228574A0 (en) 2013-12-31
EP2691371A1 (en) 2014-02-05
US8993602B2 (en) 2015-03-31
JP2014509622A (ja) 2014-04-21
RU2597423C2 (ru) 2016-09-10

Similar Documents

Publication Publication Date Title
CN103261161B (zh) 凝血因子Xa抑制剂的结晶形式
CA2633181A1 (en) Salt and polymorph of dpp-iv inhibitor
CA3261064A1 (en) TREATMENT METHODS FOR NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
CA2830965C (en) Benzoic acid salt of otamixaban
IL297206A (en) Crystalline forms of (9r, 135s)-13- {4-[5-chloro-2-(4-chloro-1h,2,3- triazol- 1-yl)phenyl] -6-oxo- 1,6-dihydropyrimidine - 1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15- tetraazatricyclo [ 12.3.1.02 6] octadeca- 1(18), 2(6), 4, 14, 16- pentaene -8-one
US7829711B2 (en) Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-C]pyridine-3-yl]-ethane-1,2-dione
CA2424565C (en) Novel crystalline forms of a factor xa inhibitor
JP2025533955A (ja) (2s,5r)-5-(2-クロロフェニル)-1-(2’-メトキシ-[1,1’-ビフェニル]-4-カルボニル)ピロリジン-2-カルボン酸の多形およびその調製プロセス
CA3180417A1 (en) Synthesis of (2s,5r)-5-(2-chlorophenyl)-1-(2'-methoxy-[1,1'-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid
HK1189584B (en) Benzoic acid salt of otamixaban
AU2005317158A1 (en) Crystalline forms of a factor Xa inhibitor
EP1819703A1 (en) Crytalline forms of a pyrazolo `3, 4-c ü pyridine factor xa inhibitor
US20140329864A1 (en) Crystalline salts of R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid
US20140343106A1 (en) Sodium Salt Of (R)-3-[6-Amino-Pyridin-3-Yl]-2-(1-Cyclohexyl-1H-Imidazol-4-Yl)-Propionic Acid
KR20160042107A (ko) 시스테인 프로테아제 억제제로서 유용한 n-[1-6-(에티닐-3-옥소-헥사하이드로-푸로[3,2-b]피롤-4-카르보닐)-3-메틸-부틸]-4-[5-플루오로-2-(4-메틸-피페라지닐)티아졸-4-일]-벤즈아미드의 염의 2형 결정질 다형체